Riddington C, Williamson L
Institute of Child Health, University of Liverpool, Alder Hey Children's Hospital, Eaton Road, Liverpool, UK, L12 2AP.
Cochrane Database Syst Rev. 2001(3):CD003149. doi: 10.1002/14651858.CD003149.
Sickle cell disease is one of the most common inherited diseases in the world, and causes haemolytic anaemia, vaso-occlusive crises and dysfunction in virtually any organ system in the body. Surgical procedures are often required. Blood transfusion regimes can be used preoperatively in an attempt to increase transport of oxygen around the body and dilute the sickled red blood cells, thus reducing the risk of vaso-occlusion.
To assess the relative risks and benefits of preoperative blood transfusion regimes in patients with sickle cell disease undergoing surgery of any type in any setting.
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group specialist trials register which comprises references identified from comprehensive electronic database searches, handsearching relevant journals and handsearching abstract books of conference proceedings. Date of the most recent search: January 2001
All randomised or quasi-randomised controlled trials comparing preoperative blood transfusion regimes to different regimes or no transfusion in patients with sickle cell disease undergoing surgery.
Both reviewers independently assessed trial quality and extracted data from the study included.
Only one trial met the inclusion criteria for the review. The trial compared an aggressive transfusion regime (decreasing sickle haemoglobin to less than 30%) to a conservative transfusion regime (increasing haemoglobin to 10 g/dl) in 604 elective operations in patients with sickle cell disease. The conservative regime was found to be as effective as the aggressive regime in preventing perioperative complications, and was associated with less transfusion related adverse events. No randomised controlled trials were found for transfusion compared to no transfusion.
REVIEWER'S CONCLUSIONS: While in general conservative therapy appears to be as effective as aggressive in preparation for surgery in sickle cell patients, further research is needed to examine the optimal regime for different surgical types, and to address whether preoperative transfusion is needed in all surgical situations.
镰状细胞病是世界上最常见的遗传性疾病之一,可导致溶血性贫血、血管阻塞性危象以及身体几乎任何器官系统的功能障碍。通常需要进行外科手术。术前可采用输血方案,试图增加体内氧气运输并稀释镰状红细胞,从而降低血管阻塞的风险。
评估镰状细胞病患者在任何环境下接受任何类型手术时,术前输血方案的相对风险和益处。
我们检索了Cochrane囊性纤维化和遗传疾病小组专业试验注册库,该注册库包含通过全面电子数据库检索、手工检索相关期刊以及手工检索会议论文摘要书籍所识别的参考文献。最近一次检索日期:2001年1月
所有比较术前输血方案与不同方案或不输血的随机或半随机对照试验,受试对象为接受手术的镰状细胞病患者。
两位综述作者独立评估试验质量并从纳入研究中提取数据。
只有一项试验符合该综述的纳入标准。该试验在604例镰状细胞病患者的择期手术中,比较了积极输血方案(将镰状血红蛋白降低至低于30%)与保守输血方案(将血红蛋白提高至10 g/dl)。结果发现,保守方案在预防围手术期并发症方面与积极方案同样有效,且与较少的输血相关不良事件相关。未发现比较输血与不输血的随机对照试验。
虽然总体而言,在为镰状细胞病患者手术做准备时,保守治疗似乎与积极治疗一样有效,但仍需要进一步研究以确定针对不同手术类型的最佳方案,以及是否在所有手术情况下都需要术前输血。